iBio licences plant-based tech for H1N1 vaccine production

By Nick Taylor

- Last updated on GMT

Related tags: Influenza

iBio has agreed in principle to license its iBioLaunch platform, which uses Nicotiana to produce therapeutics, to G-Con for the development and manufacture of plant-expressed influenza vaccines.

Plant-based production has been proposed as a rapid response, low cost alternative with the ability to massively scale up. G-Con’s GreenVax Project intends to show proof-of-concept for a large-scale vaccine production facility using Nicotiana​ plants​grown in a controlled environment.

The project will initially look at producing H1N1 vaccines. iBio believes its platform is particularly suited to producing vaccines in response to pandemics because of the speed advantages it offers over egg-based manufacture.

Non-genetically-modified plants used in iBioLaunch have short growing cycles and this, coupled to the transient nature of the gene expression technology, helps cut the time from isolating the strain to production.

When manufacture begins it can be quickly scaled-up by simply growing more plants in the contained growth facilities. G-Con will perform this process on a secure, 21-acre site at the Texas A&M Health Science Center in Bryan, Texas, US.

A 145,000 sq ft bio-production facility capable of producing 100m doses a month is being constructed at the site. The facility has been designed to complete the GreenVax Project but can be expanded without interrupting core operations.

H1N1 is the target of the GreenVax Project but iBioLaunch can be applied to seasonal influenza, other infectious diseases or cancer. Robert Kay, CEO of iBio, expects “influenza, including seasonal influenza, to be among the earliest applications of the iBioLaunch technology​”.

He added: “In the new GreenVax facility, G-Con’s modular production technology should significantly enhance the economy, speed and flexibility advantages of our system for application to a broad range of biologic products​.”

Related news

Show more

Related products

show more

A Culture of Innovation as a Differentiation

A Culture of Innovation as a Differentiation

Softigel by Procaps | 06-Dec-2021 | Product Presentation

We create safe, effective and differentiated pharmaceutical solutions and this has been our goal since day 1. The main driver of our growth is innovation...

Strategies to Achieve Successful Approval & Launch

Strategies to Achieve Successful Approval & Launch

Catalent Pharma Solutions | 03-Sep-2020 | Data Sheet

There are several key considerations to how companies should approach commercial-scale manufacturing that may aid the success of their biologic’s launch...

The Effect of Tamping Force on Bi-Layer Tablets

The Effect of Tamping Force on Bi-Layer Tablets

JRS PHARMA | 15-Aug-2020 | Technical / White Paper

Formulation of bi-layer or multi-layer tablets enables the combination of two or more drugs that may be incompatible or maybe intended for delivery at...

Related suppliers

Follow us


View more